Clinical Symptoms and Therapies for Multiple Sclerosis

Abstract

Multiple Sclerosis (MS) is a chronic form, progressive and immune mediated central nervous system disorder that affects both adults and children. MS is characterized by the development of multiple lesions with the nerve fibers in the spinal cord, optic nerves and brain. Multiple sclerosis affects the approximately 2.5 million people worldwide. A triad of symptoms characterize the disease: fatigue, changes in sensation, ataxia, muscle weakness, dysarthria, dysphagia, visual problems, chronic or acute pain, difficulties of bladder and bowel. The diagnosis of Multiple Sclerosis is made on the foundation of the signs and symptoms, with magnetic resonance imaging and additional laboratory tests playing a helpful role. Every tests are non precise and simply supply supportive indication for diagnosis. A few people have a inadequate number of “relapses” or “attacks” and remain fairly healthy for decades, others may worsen rapidly from the time of analysis, through shortened lifespan and poor excellence of the life. The prognosis is problematical to forecast; it depends on the initial symptom, subtype of the illness, the individual patient’s disorder characteristics. The substantial variability in multiple sclerosis manifestations leads to elevated figure of misdiagnoses each year, but advances in knowledge and pharmaceuticals are leading to more exact identification and successful management. Early diagnosis and management is essential in reducing the severity of disease.

  • Page Number : 29-47
  • Keywords
    Multiple sclerosis, plaques, myelin, autoimmune disease
  • DOI Number
    10.15415/jptrm.2015.31003
  • Authors
    • Ashwani Arya Department of Pharmaceutical Education and Research, BPS Women University, South Campus, Bhianswal Kalan, Sonepat, Haryana, India
    • Sahil Kumar School of Pharmacy and Emerging Science, Baddi University of Emerging Science Technology, Baddi, Solan, H.P, India
    • Rakesh K Sindhu Chitkara College of Pharmacy, Chitkara University, Rajpura, Patiala, Punjab, India

References

  • Amanda, L.H., Kevin, C.O. & David, A.H. (2014). Multiple Sclerosis. The Autoimmune Diseases, (5), 735–756
  • Arnon, R., Sela, M., Teitelbaum, B. (1995). New insights into the mechanism of action of copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo- controlled trial. Neurology, 45, 1268-76. http://dx.doi.org/10.1212/WNL.45.7.1268
  • Ascherio, A. & Munger, K.L. (2007). Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Ann. Neurol, 61 (4), 288–99. http://dx.doi.org/10.1002/ana.21117
  • Bagert, B., Camplair, P. & Bourdette, D. (2002).Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs, 16:445–455. http://dx.doi.org/10.2165/00023210-200216070-00002
  • Barnes, D., Hughes, R.A., Morris, R.W., Wade, J.O., Brown, P. & Britton T. (1997). Rondomised trial of oral and intravenous mehylprednisolone in acute relapses of multiple sclerosis. Lancet 1997, 349, 902-906. http://dx.doi.org/10.1016/S0140-6736(96)06453-7.
  • Basso, AS., Frenkel, D., Quintana, FJ., et al. (2008). Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest, 118, 1532–1543. http://dx.doi.org/10.1172/JCI33464
  • Beck, R.W. (1995). The opticneuritis treatment trial: three-year follow- up results. Arch Opthalmol, 113, 136-137. http://dx.doi.org/10.1001/archopht.1995.01100020014004
  • Benedict, R.H. & Bobholz, J.H.(2007). Multiple sclerosis. Seminars in neurology, 27 (1), 78–85. http://dx.doi.org/10.1055/s-2006-956758
  • British and Dutch, M.S.(1998). Azathioprine Trial Group. Doublemasked trial of azathioprine in multiple sclerosis. Lancet, 2, 179-180.
  • Caillier, SJ., Briggs, F., Cree, BA., et al. (2008). Uncoupling the roles of HLA-DRB1 and HLADRB5 genes in multiple sclerosis. J Immunol, 181, 5473–5480. http://dx.doi.org/10.4049/jimmunol.181.8.5473
  • Calabrese, M., Filippi, M. & Gallo, P.(2010). Cortical lesions in multiple sclerosis. Nature Reviews Neurology, 6,438-444 http://dx.doi.org/10.1038/nrneurol.2010.93
  • Chard, D., Griffin, C., McLean, M., Kapeller, P., Kapoor, R., et al. (2002). Brain metabolite changes in cortical grey matter and normal-appearing white matter in clinically early relapsingremitting multiple sclerosis. Brain,125(10), 2342-2352. http://dx.doi.org/10.1093/brain/awf240
  • Chari, D.M. (2007). Remyelination in multiple sclerosis. Int. Rev. Neurobiol, 79, 589–620. http://dx.doi.org/10.1016/S0074-7742(07)79026-8
  • Comabella, M. & Khoury, S. (2012). Immunopathogenesis of multiple sclerosis. Clinical Immunology,142(1), 2-8 http://dx.doi.org/10.1016/j.clim.2011.03.004
  • Compstom, A. & Coles, A. (2008). Multiple sclerosis. Lancet, 372: 1502-17. http://dx.doi.org/10.1016/S0140-6736(08)61620-7
  • Costello, E. (1996). Exercise prescription for individuals with multiple sclerosis. Neurology Report, 20, 24-30. http://dx.doi.org/10.1097/01253086-199620020-00016
  • Cree, B.A.C. (2013). Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler, 19, 835-843. http://dx.doi.org/10.1177/1352458512471880
  • Dyment, D.A., Ebers, G.C. & Sadovnick, A.D. (2004). Genetics of multiple sclerosis”. Lancet Neurol, 3 (92), 104–10. http://dx.doi.org/10.1016/S1474-4422(03)00663-X
  • Evangelou, N., Jackson, M. & Beeson, P.J. (1999). Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry, 67, 203– 205. http://dx.doi.org/10.1136/jnnp.67.2.203
  • Fazekas, F, Deisenhammer, F., Strasser, F.S, Nahler, G. & Mamoli, B. (1997). Randomised placebo-controlled trial of monthly intravenous-immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet, 349:589-93. http://dx.doi.org/10.1016/S0140-6736(96)09377-4
  • Filippi, M., Rocca, M.A., De, Stefano. N., Enzinger, C., Fisher, E., Horsfield, M.A., Inglese, M., Pelletier, D., Comi, G. (2011). Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch. Neurol, 68 (12),1514–1520. http://dx.doi.org/10.1001/archneurol.2011.914
  • Foxm, R.J., Bethouxm F., Goldman, M.D., Cohen, J.A. (2006). Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med, 73(1), 91-102. http://dx.doi.org/10.3949/ccjm.73.1.91
  • Franklin, R., French-Constant, C. (2008). Remyelination in the CNS: from Biology to Therapy. Nat Rev Neurosci, 9, 839-855. http://dx.doi.org/10.1038/nrn2480
  • Friedman, J.E., Lyons, M.J., Ablashl, D.V., Whitman, J.E., Edgar, M., Koskiniemi, M., Vaheri, A. & Zabriskie, JB. (1999). The association of the human herpesvirus-6 and MS. Mult Sclerosis, 5, 355–362. http://dx.doi.org/10.1177/135245859900500509 http://dx.doi.org/10.1191/135245899678846311
  • Ghaffar, O. & Feinstein, A. (2007). The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry, 20 (3): 278–285.
  • Goodin, D.S., Frohman, E.M., Garmany, G.P., et al. (2002). Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 58,169-178. http://dx.doi.org/10.1212/WNL.58.2.169
  • Granziera, C. & Sprenger, T. ( 2015). Brain Inflammation, Degeneration, and Plasticity in Multiple Sclerosis.Brain Mapping, 917–927.
  • Hafler, D.A., Compston, A., Sawcer, S., et al. (2007). Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med, 357 : 851– 862. http://dx.doi.org/10.1056/NEJMoa073493
  • Isaac, C., Genton, M., Jardine, C., Grochowski, E. & Palmer, M. (1988). Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology, 38, :1511-1515. http://dx.doi.org/10.1212/WNL.38.10.1511
  • Jezabel, Varadé., Marta García, Montojo., Belén D.L.H., Iris, Camacho., Ángel, GarcíaMartínez ., Rafael, Arroyo., Roberto, Álvarez-Lafuente. & Elena, Urcelay. (2015). Multiple
  • sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion. BBA Clinical, 3, 162–167. http://dx.doi.org/10.1016/j.bbacli.2015.02.002
  • Johnson, K.P. (2007). Control of multiple sclerosis relapses with immunomodulating agents. J. Neurol. Sci, 256 (1): 23–28. http://dx.doi.org/10.1016/j.jns.2007.01.060
  • Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J. & Lisak RP. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple
  • sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 45:1268-1276. http://dx.doi.org/10.1212/WNL.45.7.1268
  • Karussi, D., Meiner, Z., Lehmann, D., Gomori, J.M., Schwarz, A. & Linde, A. (1996). Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double - blind, placebo-controlled pilot study with monthly MRI evaluation. Neurology, 47:341-346. http://dx.doi.org/10.1212/WNL.47.2.341
  • Karussis, D. (2014). The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review. Journal of Autoimmunity, 48, 134-142. http://dx.doi.org/10.1016/j.jaut.2014.01.022
  • La, M.L., Eoli, M., Milanese, C., Salmaggi, A., Dufour, A., Torri, V. (1994). Double - blind trial of dexamethasone versus methyl prednisolone in multiple sclerosis acute relapses. Eur Neurol, 34:199-203. http://dx.doi.org/10.1159/000117038
  • Lassmann, H, Bruck, W. & Lucchinetti, C.F. (2007). The immunopathology of multiple sclerosis: an overview. Brain Pathol, 17: 210–218. http://dx.doi.org/10.1111/j.1750-3639.2007.00064.x
  • Lucchinetti, C. (2008). Pathological heterogeneity of idiopathic central nervous system demyelinating disorders. Curr Top Microbiol Immunol, 318, 19-43. http://dx.doi.org/10.1007/978-3-540-73677-6_2
  • Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (6), 707–717. http://dx.doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
  • Maeda, A., Sobel, R.A. (1996). Matrix metalloproteinases in the normal human CNS, microglial nodules and multiple sclerosis lesions. J Neuropathol Exp Neuro, 55 : 300-309. http://dx.doi.org/10.1097/00005072-199603000-00005
  • Marvin, M.G. (2012). Multiple Sclerosis Review. Pharmacy and Therapeutic. 37(3),175–184.
  • Millefiorini, E., Gasperini, C., Pozzilli, C. D., Andrea, F., Bastianello, S. & Trojano, M. (1997). Randomised placebo – controlled trial of mitozantrone in relapsing - remitting multiple sclerosis. J Neurol, 244:153-159. http://dx.doi.org/10.1007/s004150050066
  • Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H. & Honigman S.(1998). Treatment of multiple sclerosis with copaxone: implicating mechanisms of Th1 to Th2/Th3 immune- deviation. J Neuroimmunol, 92:113-21. http://dx.doi.org/10.1016/S0165-5728(98)00191-X
  • Miller, D.H. & Leary, S.M. (2007). Primary-progressive multiple sclerosis. Lancet Neurol, 6(10), 903–912. http://dx.doi.org/10.1016/S1474-4422(07)70243-0
  • Minagar, A. & Alexander, J. (2003). Blood-brain barrier disruption in multiple sclerosis. Multiple Sclerosis, 9, 540-549. http://dx.doi.org/10.1191/1352458503ms965oa
  • Myrh, KM., Raknes, G., Nyland, H., Vedeler, C. (1999). Immunoglobulin G Fc-receptor (Fc gR) IIA and IIIB polymorphisms related to disability in MS. Neurology, 52, 1771–1776. http://dx.doi.org/10.1212/WNL.52.9.1771
  • Nakahara, J., Maeda, M., Aiso, S., Suzuki, N. (2012). Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy Clinical reviews in allergy & immunology, 42 (1), 26–34 http://dx.doi.org/10.1007/s12016-011-8287-6
  • National Institute of Neurological Disorders and Stroke. (2015). Multiple sclerosis hope through research.
  • National Institutes of Health. (2010). Fact sheets multiple sclerosis.1-2.
  • Pascual, A.M., Martínez-Bisbal, M.C., Boscá, I. (2007). Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 1: 63–67. http://dx.doi.org/10.1212/01.wnl.0000265054.08610.12
  • Pivneva, T. (2009). Mechanisms Underlying the Process of Demyelination in Multiple Sclerosis. Neurophysiology, 41(5), 429-437 http://dx.doi.org/10.1007/s11062-010-9114-z
  • Polman, C.H. & Hartung H. (1995). The treatment of multiple sclerosis: current and future. Curr Opin Neurol, 8, 200-209. http://dx.doi.org/10.1097/00019052-199506000-00008
  • Poser, C.M. & Brinar, V.V. (2004). Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg, 106 (3), 147–58. http://dx.doi.org/10.1016/j.clineuro.2004.02.004
  • Prat, A., Al-Asmi, A., Duquette, P., Antel, J.P. (1999). Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy. Ann Neurol, 46:253-256. http://dx.doi.org/10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C
  • Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J. & Beutler, E. (1999). A double blind, placebocontrolled, randomised trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 1999; 111:35-44. http://dx.doi.org/10.1046/j.1525-1381.1999.09115.x
  • Rosati, G. (2001). The prevalence of multiple sclerosis in the world : an update. Neurol. Sci, 22(2), 117-39. http://dx.doi.org/10.1007/s100720170011
  • Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., Filippi, M. (2006). Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol, 5 (4), 343–354. http://dx.doi.org/10.1016/S1474-4422(06)70410-0
  • Rudick, R.A., Lee, J.C., Simon, J., Ransohoff, R.M. & Fisher, E. (2004). Defining interferon b response status in multiple sclerosis patients. Ann Neurol, 56, 548- 555. http://dx.doi.org/10.1002/ana.20224
  • Schrijver, H.M., Crusius, J.B., Uitdehaag, B.M., Garcia Gonzalez, M.A., Kostense, P.J. & Polman, CH. (1999). Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology, 52, 595– 599. http://dx.doi.org/10.1212/WNL.52.3.595
  • Smith, D.R., Weinstock-Guttman, B., Cohen. JA, et al. (2005). A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler, 11, 573-582. http://dx.doi.org/10.1191/1352458505ms1210oa
  • Sotelo, J., Martínez-Palomo, A., Ordo-ez, G., Pineda, B. (2008). Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis”. Ann. Neurol, 63 (3), 303–311. http://dx.doi.org/10.1002/ana.21316
  • Steultjens, E.M., Dekker, J., Bouter, L.M., Leemrijse, C.J., van, D. & Ende, C.H. (2005). Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clinical rehabilitation, 19 (3): 247–54. http://dx.doi.org/10.1191/0269215505cr870oa
  • Thompson, A.J. (2005). Neurorehabilitation in multilple sclerosis: foundations, facts and fiction. Current Opinion in Neurology, 18: 267-271. http://dx.doi.org/10.1097/01.wco.0000169743.37159.a0
  • Trapp, B.D., Wujek, J.R., Criste, G.A., et al. (2007). Evidence for synaptic stripping by cortical microglia. Glia, 55, 360 –368. http://dx.doi.org/10.1002/glia.20462
  • Tremlett, H.L, Luscombe, D.K. & Wiles, C.M. (1998). Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psych, 65: 362-5. http://dx.doi.org/10.1136/jnnp.65.3.362
  • Tsang, B.K. & Macdonell, .R. (2011). Multiple sclerosis- diagnosis, management and prognosis. Australian family physician, 40 (12): 948–55.
  • Tubridy, N., Behan, P.O., Capildeo, R., Chaudhuri, A., Forbes, R. & Hawkins, C.P. : The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53:466-72. http://dx.doi.org/10.1212/WNL.53.3.466
  • Weiner, H.L. (2004). Multiple sclerosis is an inflammatory T-cellmediated autoimmune disease. Arch Neurol, 61, 1613–1615 http://dx.doi.org/10.1001/archneur.61.10.1613
  • Weinshenker, B.H. (1998). The natural history of multiple sclerosis: up date. Semin Neurol, 18, 301-307. http://dx.doi.org/10.1055/s-2008-1040881
  • Weinshenker, B.G., Obrien, P.C, Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F. & Dodick, D.W. (1999). A randomised trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol, 46:878-86. http://dx.doi.org/10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
  • Weinstock-Guttman, B., Ransohoff, R.M., Kinkel, R.P., Rudick, R.A. (1995). The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol, 37, 7- 15. http://dx.doi.org/10.1002/ana.410370105
  • WHO. (2006). Neurological disorders: public health challenges, 85-94.
  • Yong, V.W., Chabot, S., Stuve, O. & Williams, G. (1998). Interferon beta in the treatment of multiple sclerosis-mechanisms of action. Neurology, 51:682-689. http://dx.doi.org/10.1212/WNL.51.3.682
  • Yudkin, P.L., Ellison, G.W., Ghezzi, A., Goodkin, D.E., Hughes, R.A. & Mc Pherson, K. (1991). Overview of azathioprine treatment in multiple sclerosis. Lancet, 338:1051-55. http://dx.doi.org/10.1016/0140-6736(91)91909-E

  • Published Date : 2015-05-20